Regulation of progesterone receptor signaling by BRCA1 in mammary cancer

Inherited mutations of the BRCA1 gene (chromosome 17q21), a tumor suppressor, lead to an increased risk of breast cancer, ovarian cancer, and several other hormone-responsive tumor types. Over the last ten years, BRCA1 has been found to play major roles in DNA damage signaling, repair, and cell cycle checkpoints. In addition, unfolding evidence suggests that BRCA1 functions as a co-regulator for steroid hormone receptors and modulates steroid hormone action. In this paper, we will briefly review this evidence and present a model to address the role of the progesterone and estrogen receptors in BRCA1 mutant mammary carcinogenesis. Finally, we will consider some of the clinical implications of this model.

[1]  Progestins both stimulate and inhibit breast cancer cell cycle progression while increasing expression of transforming growth factor alpha, epidermal growth factor receptor, c-fos, and c-myc genes. , 1991, Molecular and cellular biology.

[2]  Steven E. Bayer,et al.  A strong candidate for the breast and ovarian cancer susceptibility gene BRCA1. , 1994, Science.

[3]  Junzhe Xu,et al.  The developmental pattern of Brca1 expression implies a role in differentiation of the breast and other tissues , 1995, Nature Genetics.

[4]  P. Leder,et al.  Expression of Brca1 is associated with terminal differentiation of ectodermally and mesodermally derived tissues in mice. , 1995, Genes & development.

[5]  L. Chodosh,et al.  Brca2 is coordinately regulated with Brca1 during proliferation and differentiation in mammary epithelial cells. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[6]  J Isola,et al.  Distinct somatic genetic changes associated with tumor progression in carriers of BRCA1 and BRCA2 germ-line mutations. , 1997, Cancer research.

[7]  Simak Ali,et al.  An important role for BRCA1 in breast cancer progression is indicated by its loss in a large proportion of non‐familial breast cancers , 1998, International journal of cancer.

[8]  B. Karlan,et al.  Localization of human BRCA1 and its loss in high-grade, non-inherited breast carcinomas , 1999, Nature Genetics.

[9]  Thomas Ried,et al.  Conditional mutation of Brca1 in mammary epithelial cells results in blunted ductal morphogenesis and tumour formation , 1999, Nature Genetics.

[10]  C. Lange,et al.  Hypothesis: Progesterone primes breast cancer cells for cross-talk with proliferative or antiproliferative signals. , 1999, Molecular endocrinology.

[11]  M. Erdos,et al.  BRCA1 inhibition of estrogen receptor signaling in transfected cells. , 1999, Science.

[12]  I. Andrulis,et al.  Frequency of p53 mutations in breast carcinomas from Ashkenazi Jewish carriers of BRCA1 mutations. , 1999, Journal of the National Cancer Institute.

[13]  J. Herman,et al.  Promoter hypermethylation and BRCA1 inactivation in sporadic breast and ovarian tumors. , 2000, Journal of the National Cancer Institute.

[14]  W. Lee,et al.  BRCA1 mediates ligand-independent transcriptional repression of the estrogen receptor , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[15]  T. Walsh,et al.  Tamoxifen and breast cancer incidence among women with inherited mutations in BRCA1 and BRCA2: National Surgical Adjuvant Breast and Bowel Project (NSABP-P1) Breast Cancer Prevention Trial. , 2001, JAMA.

[16]  M. Erdos,et al.  Role of direct interaction in BRCA1 inhibition of estrogen receptor activity , 2001, Oncogene.

[17]  S. Narod.  Hormonal Prevention of Hereditary Breast Cancer , 2001, Annals of the New York Academy of Sciences.

[18]  M. J. van de Vijver,et al.  The pathology of familial breast cancer: predictive value of immunohistochemical markers estrogen receptor, progesterone receptor, HER-2, and p53 in patients with mutations in BRCA1 and BRCA2. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[19]  H. Kawai,et al.  Direct interaction between BRCA1 and the estrogen receptor regulates vascular endothelial growth factor (VEGF) transcription and secretion in breast cancer cells , 2002, Oncogene.

[20]  M. Erdos,et al.  p300 Modulates the BRCA1 inhibition of estrogen receptor activity. , 2002, Cancer research.

[21]  C. Schairer.  Progesterone receptors – animal models and cell signalling in breast cancer: Implications for breast cancer of inclusion of progestins in hormone replacement therapies , 2002, Breast Cancer Research.

[22]  E. Kubista,et al.  Brca1 regulates in vitro differentiation of mammary epithelial cells , 2002, Oncogene.

[23]  Douglas F Easton,et al.  Cancer Incidence in BRCA1 mutation carriers. , 2002, Journal of the National Cancer Institute.

[24]  Susan L Neuhausen,et al.  Prophylactic oophorectomy in carriers of BRCA1 or BRCA2 mutations. , 2002, The New England journal of medicine.

[25]  J. Isola,et al.  Haplo-insufficiency of BRCA1 in sporadic breast cancer. , 2003, Cancer research.

[26]  E. Rosen,et al.  BRCA1 gene in breast cancer , 2003, Journal of cellular physiology.

[27]  K. Offit,et al.  Increased Progesterone Receptor Expression in Benign Epithelium of BRCA1-Related Breast Cancers , 2004, Cancer Research.

[28]  J. Lydon,et al.  Progesterone Receptors in Mammary Gland Development and Tumorigenesis , 2003, Journal of Mammary Gland Biology and Neoplasia.

[29]  C. Deng,et al.  Effect of bilateral oophorectomy on mammary tumor formation in BRCA1 mutant mice. , 2005, Oncology reports.

[30]  C. Isaacs,et al.  BRCA1 in hormonal carcinogenesis: basic and clinical research. , 2005, Endocrine-related cancer.

[31]  Minglin Li,et al.  Promotion of mammary cancer development by tamoxifen in a mouse model of Brca1-mutation-related breast cancer , 2005, Oncogene.

[32]  E. Rosen,et al.  Structural determinants of the BRCA1 : estrogen receptor interaction , 2005, Oncogene.

[33]  C. Isaacs,et al.  BRCA1 in hormonal carcinogenesis: basic and clinical research. , 2005, Endocrine-related cancer.

[34]  E. Rosen,et al.  Regulation of the estrogen-inducible gene expression profile by the breast cancer susceptibility gene BRCA1. , 2005, Endocrinology.

[35]  C. Y. Wang,et al.  Estrogen-plus-progestin use and mammographic density in postmenopausal women: Women's Health Initiative randomized trial. , 2005, Journal of the National Cancer Institute.

[36]  E. Rosen,et al.  The breast cancer susceptibility gene BRCA1 regulates progesterone receptor signaling in mammary epithelial cells. , 2006, Molecular endocrinology.